Lake Street analyst Frank Takkinen raised the firm’s price target on Beta Bionics (BBNX) to $35 from $30 and keeps a Buy rating on the shares after the company reported top and bottom line upside in Q3 and raised guidance. A war chest of $274M of cash at Q3 end supports “aggressive investment,” adds the analyst, who thinks shares deserve a premium valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $31 from $26 at Stifel
- Beta Bionics price target raised to $33 from $26 at Goldman Sachs
- Beta Bionics price target raised to $23 from $17 at Baird
- Beta Bionics price target raised to $32 from $26 at Piper Sandler
- Beta Bionics Reports Strong Q3 Growth and Raises Guidance